Yuji Wakamatsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuji Wakamatsu has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Koichi Nagashima
Division of Cardiology, Department of Medicine Nihon University School of Medicine Tokyo Japan
43 shared publications - Yasuo Okumura
Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
29 shared publications - Ryuta Watanabe
Division of Cardiology, Department of Medicine Nihon University School of Medicine Tokyo Japan
22 shared publications - Moyuru Hirata
Division of Cardiology, Department of Medicine Nihon University School of Medicine Tokyo Japan
18 shared publications Naoto Otsuka
Division of Cardiology, Department of Medicine Nihon University School of Medicine Tokyo Japan
18 shared publications- Shu Hirata
Division of Cardiology, Department of Medicine Nihon University School of Medicine Tokyo Japan
18 shared publications
Latest Publications
- Open Access
- 21 August 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (9)
Irrigation-dependent acute ganglionated plexus modulation during variable-loop pulsed field ablation
Clinical trial registration: UMIN Clinical Trials Registry, UMIN000057894.
- 21 August 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (9)
Open AccessIrrigation-dependent acute ganglionated plexus modulation during variable-loop pulsed field ablation
Clinical trial registration: UMIN Clinical Trials Registry, UMIN000057894.
- 1 August 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (10) , 2241-2250
Accurate Diagnosis of Atrioventricular Nodal Reentrant Tachycardia With Very Short His‐Atrial Interval and Earliest Activation in the Proximal Coronary Sinus
Introduction: Differential diagnoses in atrioventricular nodal reentrant tachycardia (AVNRT) with His‐atrial (HA) interval of < 70 ms and earliest atrial activation site (EAAS) in the proximal coronary sinus (pCS) include slow‐fast AVNRT with inferior deviation of the fast pathway (FP) and slow‐slow AVNRT with a lower common pathway (LCP). Therefore, we examined the electrophysiological and anatomical characteristics distinguishing slow‐fast AVNRT with inferior FP deviation from slow‐slow AVNRT with an LCP. Methods: Analyzed were 32 AVNRTs with HA intervals of < 70 ms and EAAS in pCS. During ablation at the EAAS, patients with atrio‐His (AH) interval prolongation leading to abandonment ( n = 7) were classified as slow‐fast AVNRT phenotype, while those with successful ablation without AH prolongation ( n = 25) were classified as slow‐slow AVNRT phenotype. Results: Triple antegrade AVN physiology, dual retrograde AVN physiology, and AH block during AVNRT were observed only in the slow‐slow AVNRT group. A ΔHA > 15 ms occurred more often in the slow‐slow AVNRT group (82% vs. 17%, p = 0.009). The AH VP ‐AH AVNRT —defined as the AH interval during right ventricular overdrive pacing minus that during AVNRT—was shorter in the slow‐slow AVNRT group (24 ± 24 vs. 1 ± 15 ms, p = 0.02). The His‐EAAS distance was shorter in the slow‐fast AVNRT group (7.3 ± 2.3 vs. 16.9 ± 4.9 mm, p < 0.001). Conclusion: In cases of AVNRT with an HA interval < 70 ms and EAAS in the pCS, the slow‐slow AVNRT phenotype is more prevalent than the slow‐fast AVNRT phenotype. The shorter AH VP ‐AH AVNRT and the His‐EAAS distance may help differentiate them.
- 1 August 2026
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 37 (10) , 2241-2250
Accurate Diagnosis of Atrioventricular Nodal Reentrant Tachycardia With Very Short His‐Atrial Interval and Earliest Activation in the Proximal Coronary Sinus
Introduction: Differential diagnoses in atrioventricular nodal reentrant tachycardia (AVNRT) with His‐atrial (HA) interval of < 70 ms and earliest atrial activation site (EAAS) in the proximal coronary sinus (pCS) include slow‐fast AVNRT with inferior deviation of the fast pathway (FP) and slow‐slow AVNRT with a lower common pathway (LCP). Therefore, we examined the electrophysiological and anatomical characteristics distinguishing slow‐fast AVNRT with inferior FP deviation from slow‐slow AVNRT with an LCP. Methods: Analyzed were 32 AVNRTs with HA intervals of < 70 ms and EAAS in pCS. During ablation at the EAAS, patients with atrio‐His (AH) interval prolongation leading to abandonment ( n = 7) were classified as slow‐fast AVNRT phenotype, while those with successful ablation without AH prolongation ( n = 25) were classified as slow‐slow AVNRT phenotype. Results: Triple antegrade AVN physiology, dual retrograde AVN physiology, and AH block during AVNRT were observed only in the slow‐slow AVNRT group. A ΔHA > 15 ms occurred more often in the slow‐slow AVNRT group (82% vs. 17%, p = 0.009). The AH VP ‐AH AVNRT —defined as the AH interval during right ventricular overdrive pacing minus that during AVNRT—was shorter in the slow‐slow AVNRT group (24 ± 24 vs. 1 ± 15 ms, p = 0.02). The His‐EAAS distance was shorter in the slow‐fast AVNRT group (7.3 ± 2.3 vs. 16.9 ± 4.9 mm, p < 0.001). Conclusion: In cases of AVNRT with an HA interval < 70 ms and EAAS in the pCS, the slow‐slow AVNRT phenotype is more prevalent than the slow‐fast AVNRT phenotype. The shorter AH VP ‐AH AVNRT and the His‐EAAS distance may help differentiate them.
- Open Access
- 26 December 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (6)
Undiagnostic Heart Failure With Preserved Ejection Fraction in Atrial Fibrillation Patients Undergoing Catheter Ablation
Background: Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) often coexist, but the prevalence of HFpEF among AF patients undergoing catheter ablation (CA) remains unclear. Methods: We studied 127 AF patients with preserved ejection fraction (≥ 50%) undergoing initial CA. The Heart Failure Association Pre‐test assessment, Echocardiography and natriuretic peptides, Functional testing, and Final etiology (HFA‐PEFF) score was assessed 2 weeks before and 1 year after CA. Patients were grouped as low (0–1), intermediate (2–4), or high (5–6). The primary endpoint was AF freedom at 1 and 2 years; secondary endpoints were changes in HFA‐PEFF score; tertiary endpoint was predictors of score improvement. Results: Of 127 patients, 30 (23.6%) had HFpEF (score ≥ 5), 76 (59.8%) suspected (2–4), and 21 (16.5%) unlikely (≤ 1). Median follow‐up 24.4[ 12.5–29.5] months. AF freedom at 1 year was high (86.4%, 91.7%, 89.7%; p = 0.66). Higher baseline score correlated with older age, female sex, hypertension, larger left atrial volume index (LAVI), elevated average E / e ′, and increased left ventricular mass index. We divided patients into two groups: those with ≥ 1‐point score improvement after CA ( n = 89, 70.1%) and those whose score remained unchanged or worsened ( n = 38, 29.9%). Improvement was associated with older age, larger LAVI, higher average E / e ′, and elevated N‐terminal pro‐B‐type natriuretic peptide. Multivariate analysis identified septal e' and LAVI as predictors. No patients had a score ≥ 5 at 1 year. Conclusions: HFpEF or suspected HFpEF was common in AF CA candidates but not linked to recurrence. CA remarkably improved HFpEF features, suggesting reversibility.
- 26 December 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (6)
Open AccessUndiagnostic Heart Failure With Preserved Ejection Fraction in Atrial Fibrillation Patients Undergoing Catheter Ablation
Background: Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) often coexist, but the prevalence of HFpEF among AF patients undergoing catheter ablation (CA) remains unclear. Methods: We studied 127 AF patients with preserved ejection fraction (≥ 50%) undergoing initial CA. The Heart Failure Association Pre‐test assessment, Echocardiography and natriuretic peptides, Functional testing, and Final etiology (HFA‐PEFF) score was assessed 2 weeks before and 1 year after CA. Patients were grouped as low (0–1), intermediate (2–4), or high (5–6). The primary endpoint was AF freedom at 1 and 2 years; secondary endpoints were changes in HFA‐PEFF score; tertiary endpoint was predictors of score improvement. Results: Of 127 patients, 30 (23.6%) had HFpEF (score ≥ 5), 76 (59.8%) suspected (2–4), and 21 (16.5%) unlikely (≤ 1). Median follow‐up 24.4[ 12.5–29.5] months. AF freedom at 1 year was high (86.4%, 91.7%, 89.7%; p = 0.66). Higher baseline score correlated with older age, female sex, hypertension, larger left atrial volume index (LAVI), elevated average E / e ′, and increased left ventricular mass index. We divided patients into two groups: those with ≥ 1‐point score improvement after CA ( n = 89, 70.1%) and those whose score remained unchanged or worsened ( n = 38, 29.9%). Improvement was associated with older age, larger LAVI, higher average E / e ′, and elevated N‐terminal pro‐B‐type natriuretic peptide. Multivariate analysis identified septal e' and LAVI as predictors. No patients had a score ≥ 5 at 1 year. Conclusions: HFpEF or suspected HFpEF was common in AF CA candidates but not linked to recurrence. CA remarkably improved HFpEF features, suggesting reversibility.
- Open Access
- 27 October 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (5)
Wall Thickness‐Guided vs. Voltage‐Guided Pulmonary Vein Isolation for Atrial Fibrillation
Background: The efficacy and safety of tailored pulmonary vein isolation (PVI) guided by either left atrial wall thickness (LAWT) or bipolar voltage remain unclear. Objective: The aim of this prospective study was to evaluate the efficacy and safety of each ablation strategy. Methods: We conducted a prospective analysis of 97 patients with non‐valvular atrial fibrillation (AF) who underwent an initial RF catheter ablation procedure known as an extensive encircling PVI. Fifty patients underwent PVI using a wall thickness (WT)‐guided approach using ADAS 3D software and 47 patients using a voltage‐guided approach. In each strategy, high‐power short‐duration (HPSD) ablation was applied to regions with increased LAWT or elevated bipolar voltage, respectively, while very high‐power short‐duration (vHPSD) ablation was delivered to the remaining regions. Results: The first‐pass PVI rate tended to be higher in the WT‐guided group compared to the Voltage‐guided group (43 [86%] vs. 34 [72%], p = 0.09), and the incidence of acute PV reconnection (APVR) tended to be lower (5 [10%] vs. 11 [23%], p = 0.07). The proportion of patients with PV gaps (defined as the combined occurrence of first‐pass failure and/or APVR) was significantly lower in the WT‐guided group (10 [20%] vs. 18 [38%], p = 0.04). The multivariable‐adjusted analysis demonstrated that WT‐guided ablation was significantly more effective than Voltage‐guided ablation in preventing PV gaps. Both ablation strategies were performed without any procedural complications. Conclusions: WT‐guided ablation was associated with a significantly lower incidence of PV gaps than a conventional bipolar voltage‐guided strategy.
- 27 October 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (5)
Open AccessWall Thickness‐Guided vs. Voltage‐Guided Pulmonary Vein Isolation for Atrial Fibrillation
Background: The efficacy and safety of tailored pulmonary vein isolation (PVI) guided by either left atrial wall thickness (LAWT) or bipolar voltage remain unclear. Objective: The aim of this prospective study was to evaluate the efficacy and safety of each ablation strategy. Methods: We conducted a prospective analysis of 97 patients with non‐valvular atrial fibrillation (AF) who underwent an initial RF catheter ablation procedure known as an extensive encircling PVI. Fifty patients underwent PVI using a wall thickness (WT)‐guided approach using ADAS 3D software and 47 patients using a voltage‐guided approach. In each strategy, high‐power short‐duration (HPSD) ablation was applied to regions with increased LAWT or elevated bipolar voltage, respectively, while very high‐power short‐duration (vHPSD) ablation was delivered to the remaining regions. Results: The first‐pass PVI rate tended to be higher in the WT‐guided group compared to the Voltage‐guided group (43 [86%] vs. 34 [72%], p = 0.09), and the incidence of acute PV reconnection (APVR) tended to be lower (5 [10%] vs. 11 [23%], p = 0.07). The proportion of patients with PV gaps (defined as the combined occurrence of first‐pass failure and/or APVR) was significantly lower in the WT‐guided group (10 [20%] vs. 18 [38%], p = 0.04). The multivariable‐adjusted analysis demonstrated that WT‐guided ablation was significantly more effective than Voltage‐guided ablation in preventing PV gaps. Both ablation strategies were performed without any procedural complications. Conclusions: WT‐guided ablation was associated with a significantly lower incidence of PV gaps than a conventional bipolar voltage‐guided strategy.
- Open Access
- 26 September 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (5) , e70199
Prospective Multicenter Registry to Investigate the Clinical Feasibility of Combination Workflow With 90 W/4 s and Ablation Index‐Guided 50 W Ablation (PRECISE—COMBO 90 W/50 W Study)
Background: High‐power short‐duration (HPSD) ablation is an established therapy for pulmonary vein (PV) isolation (PVI) in atrial fibrillation (AF), aiming to form efficient transmural lesions. Very HPSD (vHPSD) can further shorten ablation time but may increase the risk of acute PVI failure compared with HPSD. A combined HPSD and vHPSD strategy (90 W/50 W combination workflow) potentially balances efficiency and durability, though its clinical feasibility remains unknown. Therefore, this multicenter registry evaluated the acute and long‐term efficacy of a 90 W/50 W combination workflow for PVI in patients with paroxysmal AF. Methods: In this prospective study, a total of 101 consecutive patients with paroxysmal AF underwent PVI using radiofrequency ablation with a 90 W/50 W combination workflow. We evaluated acute outcomes, including first‐pass isolation and acute PV reconnection, and monitored atrial tachyarrhythmia recurrences over 12 months. Results: Median PVI procedure time was 35 min, with total procedure time at 105 min. First‐pass PVI was achieved in 58.4% of patients, including 74.3% in the right PV and 72.3% in the left PV. Acute PV reconnection occurred in 31.7% (32/101). In multivariate analysis, carina sites independently predicted acute PVI failure in both HPSD and vHPSD groups, while contact force also predicted failure in the HPSD group. After 1 year, 89.9% of patients remained free from documented atrial tachyarrhythmias. Conclusion: The 90 W/50 W combination workflow did not notably shorten procedure time or enhance first‐pass success. More standardized strategies, particularly in carina segments with higher contact force and ablation index under HPSD, may be required to ensure optimal lesion durability and favorable outcomes.
- 26 September 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (5) , e70199
Open AccessProspective Multicenter Registry to Investigate the Clinical Feasibility of Combination Workflow With 90 W/4 s and Ablation Index‐Guided 50 W Ablation (PRECISE—COMBO 90 W/50 W Study)
Background: High‐power short‐duration (HPSD) ablation is an established therapy for pulmonary vein (PV) isolation (PVI) in atrial fibrillation (AF), aiming to form efficient transmural lesions. Very HPSD (vHPSD) can further shorten ablation time but may increase the risk of acute PVI failure compared with HPSD. A combined HPSD and vHPSD strategy (90 W/50 W combination workflow) potentially balances efficiency and durability, though its clinical feasibility remains unknown. Therefore, this multicenter registry evaluated the acute and long‐term efficacy of a 90 W/50 W combination workflow for PVI in patients with paroxysmal AF. Methods: In this prospective study, a total of 101 consecutive patients with paroxysmal AF underwent PVI using radiofrequency ablation with a 90 W/50 W combination workflow. We evaluated acute outcomes, including first‐pass isolation and acute PV reconnection, and monitored atrial tachyarrhythmia recurrences over 12 months. Results: Median PVI procedure time was 35 min, with total procedure time at 105 min. First‐pass PVI was achieved in 58.4% of patients, including 74.3% in the right PV and 72.3% in the left PV. Acute PV reconnection occurred in 31.7% (32/101). In multivariate analysis, carina sites independently predicted acute PVI failure in both HPSD and vHPSD groups, while contact force also predicted failure in the HPSD group. After 1 year, 89.9% of patients remained free from documented atrial tachyarrhythmias. Conclusion: The 90 W/50 W combination workflow did not notably shorten procedure time or enhance first‐pass success. More standardized strategies, particularly in carina segments with higher contact force and ablation index under HPSD, may be required to ensure optimal lesion durability and favorable outcomes.
- Open Access
- 19 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e043484
Temporal Changes in Epicardial Adipose Tissue and Left Atrial Substrate After Atrial Fibrillation Ablation: Implications for Procedural Success
Background: Ganglionated plexi (GPs) within epicardial adipose tissue (EAT) are involved in the initiation and maintenance of atrial fibrillation (AF), yet the effects of catheter ablation on EAT volume and GP activity remain unclear. Methods: A prospective 2‐part study was conducted. Study 1 included 120 patients undergoing initial AF ablation, with pre‐ and 1‐year postablation computed tomography used to assess changes in EAT and left atrial wall characteristics. Body composition, biomarkers, and echocardiographic variables were also evaluated. Study 2 included 20 patients undergoing redo ablation for recurrent AF, in whom vagal responses elicited by high‐frequency stimulation in 5 major left atrial GP areas were compared. Results: In study 1, significant reductions in total EAT (median, 116 [interquartile range (IQR), 86–153] to 103 [IQR, 71–138] mL; P P P P <0.001), and decreased EAT computed tomography values. Multivariable analysis showed that AF recurrence was significantly associated with changes in EAT volume. In study 2, GP responses reemerged during redo ablation, particularly in the inferior right GP, alongside increases in EAT volume. Conclusions: Postablation maintenance of sinus rhythm was associated with a reduction in EAT volume. AF recurrence was associated with EAT expansion, compositional changes, and GP reactivation. Further investigation is needed to clarify clinical implications of these findings.
- 19 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (16) , e043484
Open AccessTemporal Changes in Epicardial Adipose Tissue and Left Atrial Substrate After Atrial Fibrillation Ablation: Implications for Procedural Success
Background: Ganglionated plexi (GPs) within epicardial adipose tissue (EAT) are involved in the initiation and maintenance of atrial fibrillation (AF), yet the effects of catheter ablation on EAT volume and GP activity remain unclear. Methods: A prospective 2‐part study was conducted. Study 1 included 120 patients undergoing initial AF ablation, with pre‐ and 1‐year postablation computed tomography used to assess changes in EAT and left atrial wall characteristics. Body composition, biomarkers, and echocardiographic variables were also evaluated. Study 2 included 20 patients undergoing redo ablation for recurrent AF, in whom vagal responses elicited by high‐frequency stimulation in 5 major left atrial GP areas were compared. Results: In study 1, significant reductions in total EAT (median, 116 [interquartile range (IQR), 86–153] to 103 [IQR, 71–138] mL; P P P P <0.001), and decreased EAT computed tomography values. Multivariable analysis showed that AF recurrence was significantly associated with changes in EAT volume. In study 2, GP responses reemerged during redo ablation, particularly in the inferior right GP, alongside increases in EAT volume. Conclusions: Postablation maintenance of sinus rhythm was associated with a reduction in EAT volume. AF recurrence was associated with EAT expansion, compositional changes, and GP reactivation. Further investigation is needed to clarify clinical implications of these findings.
- Open Access
- 5 May 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (3) , e70083
Clinical insights into the role of bepridil in recurrence prevention after ablation of persistent atrial fibrillation
Background: The role of bepridil in preventing atrial fibrillation (AF) recurrence following ablation for persistent atrial fibrillation (PerAF) remains uncertain, particularly in patients with severe atrial substrates.Methods: This retrospective study included 232 consecutive PerAF patients who underwent AF ablation between 2014 and 2019. Among them, 162 received bepridil for 3 months post‐ablation (Bepridil group), while 70 received no antiarrhythmic drugs (No‐AADs group). Baseline characteristics, procedural details, and outcomes were compared. Kaplan–Meier analysis and Cox regression models were used to evaluate AF/atrial tachycardia (AT) recurrence, with bepridil use treated as a time‐dependent covariable.Results: The Bepridil group had a higher body mass index (25.1 ± 3.7 vs. 23.8 ± 3.9), a higher prevalence of patients with a LAD >40 mm and a LAV >50 mL (67.9% vs. 47.1%, 64.2% vs. 48.5%, respectively), and lower left atrial appendage flow velocity (37.6 ± 15.0 vs. 42.7 ± 20.5 cm/min). They more frequently underwent intracardiac atrial cardioversion (61.7% vs. 40.0%) and additional extra‐pulmonary vein ablation (35.2% vs. 15.7%), but were less likely to receive balloon‐based ablation (39.5% vs. 62.9%) (p < 0.05 for all comparison). During a median follow‐up of 23.3 months, AF/AT‐free survival at 2 years was comparable between the Bepridil and No‐AADs groups (80.4% vs. 81.7%; p = 0.61). This finding remained consistent after adjusting for baseline characteristics and considering bepridil as a time‐dependent covariable. No bepridil‐related adverse events occurred.Conclusion: Bepridil may have a limited role in preventing AF/AT recurrence in PerAF patients, particularly those with severe atrial substrates. However, its overall impact appears to be small, warranting further investigation.
- 5 May 2025
- Published by Wiley in Journal of Arrhythmia
- Vol. 41 (3) , e70083
Open AccessClinical insights into the role of bepridil in recurrence prevention after ablation of persistent atrial fibrillation
Background: The role of bepridil in preventing atrial fibrillation (AF) recurrence following ablation for persistent atrial fibrillation (PerAF) remains uncertain, particularly in patients with severe atrial substrates.Methods: This retrospective study included 232 consecutive PerAF patients who underwent AF ablation between 2014 and 2019. Among them, 162 received bepridil for 3 months post‐ablation (Bepridil group), while 70 received no antiarrhythmic drugs (No‐AADs group). Baseline characteristics, procedural details, and outcomes were compared. Kaplan–Meier analysis and Cox regression models were used to evaluate AF/atrial tachycardia (AT) recurrence, with bepridil use treated as a time‐dependent covariable.Results: The Bepridil group had a higher body mass index (25.1 ± 3.7 vs. 23.8 ± 3.9), a higher prevalence of patients with a LAD >40 mm and a LAV >50 mL (67.9% vs. 47.1%, 64.2% vs. 48.5%, respectively), and lower left atrial appendage flow velocity (37.6 ± 15.0 vs. 42.7 ± 20.5 cm/min). They more frequently underwent intracardiac atrial cardioversion (61.7% vs. 40.0%) and additional extra‐pulmonary vein ablation (35.2% vs. 15.7%), but were less likely to receive balloon‐based ablation (39.5% vs. 62.9%) (p < 0.05 for all comparison). During a median follow‐up of 23.3 months, AF/AT‐free survival at 2 years was comparable between the Bepridil and No‐AADs groups (80.4% vs. 81.7%; p = 0.61). This finding remained consistent after adjusting for baseline characteristics and considering bepridil as a time‐dependent covariable. No bepridil‐related adverse events occurred.Conclusion: Bepridil may have a limited role in preventing AF/AT recurrence in PerAF patients, particularly those with severe atrial substrates. However, its overall impact appears to be small, warranting further investigation.
- Open Access
- 1 April 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (6) , 1293-1302
Real‐World Impact of Steerable Sheaths for Paroxysmal Atrial Fibrillation Catheter Ablation: The INSIGHT Study
Introduction: In atrial fibrillation (AF) ablation procedures, the CARTO VIZIGO Bidirectional Guiding Sheath has previously shown promising results in reducing fluoroscopy times without compromising clinical effectiveness or safety compared with non‐steerable sheaths.Methods: This non‐randomized, multicenter, retrospective cohort study (INSIGHT) aimed to determine the real‐world impact of the VIZIGO sheath on procedural efficiency, clinical effectiveness, and safety in paroxysmal AF (PAF) catheter ablation. Consecutive adults who underwent de novo radiofrequency (RF) ablation for PAF with a non‐VIZIGO sheath (January 2019–July 2021) or VIZIGO sheath (January 2020–July 2021) were included. Procedural characteristics, primary adverse events (PAEs), and 12‐month effectiveness (freedom from repeat ablation or recurrent atrial arrhythmia) were evaluated.Results: Of 199 patients included (mean age, 69.7 years; 59.3% male), 97 had ablation with a VIZIGO sheath and 102 with a non‐VIZIGO sheath. Significantly shorter mean times were achieved in the VIZIGO vs. non‐VIZIGO group for time to left PVI (18.1 ± 7.5 vs. 19.9 ± 5.6 min, p = 0.046), right PVI (16.5 ± 6.1 vs. 23.1 ± 9.9 min, p < 0.001), total PVI (34.6 ± 9.7 vs. 42.9 ± 11.4 min, p = 0.002), and fluoroscopy time (7.3 ± 10.4 vs. 18.3 ± 13.3 min, p < 0.001). Mean fluoroscopy dose was significantly lower (45.9 ± 112.0 vs. 139.5 ± 251.5 mGy, p < 0.001) with VIZIGO vs. non‐VIZIGO sheaths. Catheter stability was comparable between groups. PAE rates were similar in the VIZIGO (3.1%) and non‐VIZIGO (4.9%) groups. Freedom from repeat ablation and recurrent atrial arrhythmia at 12 months were also similar in the two groups.Conclusion: These real‐world data demonstrate that use of the VIZIGO sheath in PAF ablation procedures allows for significantly lower fluoroscopy time and dose with significantly shorter PVI isolation time, without compromising acute and long‐term effectiveness or safety.
- 1 April 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (6) , 1293-1302
Open AccessReal‐World Impact of Steerable Sheaths for Paroxysmal Atrial Fibrillation Catheter Ablation: The INSIGHT Study
Introduction: In atrial fibrillation (AF) ablation procedures, the CARTO VIZIGO Bidirectional Guiding Sheath has previously shown promising results in reducing fluoroscopy times without compromising clinical effectiveness or safety compared with non‐steerable sheaths.Methods: This non‐randomized, multicenter, retrospective cohort study (INSIGHT) aimed to determine the real‐world impact of the VIZIGO sheath on procedural efficiency, clinical effectiveness, and safety in paroxysmal AF (PAF) catheter ablation. Consecutive adults who underwent de novo radiofrequency (RF) ablation for PAF with a non‐VIZIGO sheath (January 2019–July 2021) or VIZIGO sheath (January 2020–July 2021) were included. Procedural characteristics, primary adverse events (PAEs), and 12‐month effectiveness (freedom from repeat ablation or recurrent atrial arrhythmia) were evaluated.Results: Of 199 patients included (mean age, 69.7 years; 59.3% male), 97 had ablation with a VIZIGO sheath and 102 with a non‐VIZIGO sheath. Significantly shorter mean times were achieved in the VIZIGO vs. non‐VIZIGO group for time to left PVI (18.1 ± 7.5 vs. 19.9 ± 5.6 min, p = 0.046), right PVI (16.5 ± 6.1 vs. 23.1 ± 9.9 min, p < 0.001), total PVI (34.6 ± 9.7 vs. 42.9 ± 11.4 min, p = 0.002), and fluoroscopy time (7.3 ± 10.4 vs. 18.3 ± 13.3 min, p < 0.001). Mean fluoroscopy dose was significantly lower (45.9 ± 112.0 vs. 139.5 ± 251.5 mGy, p < 0.001) with VIZIGO vs. non‐VIZIGO sheaths. Catheter stability was comparable between groups. PAE rates were similar in the VIZIGO (3.1%) and non‐VIZIGO (4.9%) groups. Freedom from repeat ablation and recurrent atrial arrhythmia at 12 months were also similar in the two groups.Conclusion: These real‐world data demonstrate that use of the VIZIGO sheath in PAF ablation procedures allows for significantly lower fluoroscopy time and dose with significantly shorter PVI isolation time, without compromising acute and long‐term effectiveness or safety.
- 12 December 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (2) , 521-524
The Pitfalls of Capture/Fusion Beats: Diagnostic Challenges in Wide QRS Complex Tachycardia
- 12 December 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (2) , 521-524
The Pitfalls of Capture/Fusion Beats: Diagnostic Challenges in Wide QRS Complex Tachycardia
- Open Access
Fractionated Potential-Guided Cryoablation Targeting Termination of Atrioventricular Nodal Reentrant Tachycardia While Avoiding the Compact Node Electrogram
Background: Fractionated potential (FP) ablation during atrioventricular nodal reentrant tachycardia (AVNRT), is an effective strategy that minimizes redundant radiofrequency (RF) applications. This study aimed to evaluate the utility of cryoablation targeting FPs to effectively terminate AVNRT while further minimizing redundant cryoapplications. Moreover, we observed what appeared to be compact AVN (cAVN) or proximal His potentials—tiny, dull potentials (TDPs) with continuity to the His potential during sinus rhythm (SR) and AVNRT—in the anteroseptal area. The second aim of this study was to explore the significance of those potentials. Methods: Analyzed were 53 slow-fast AVNRT patients who underwent ablation procedures. Ultra-high resolution activation maps in the triangle of Koch were obtained during SR (n=34) and AVNRT (n=46). TDPs during SR and AVNRT in the anteroseptal area were identified and annotated using the LUMIPOINT Activation Search tool. Results: FP areas were observed in 19 patients (56%) during SR and in 46 (100%) during AVNRT. This area corresponded to the AVNRT termination and/or successful ablation site in all, with peak numbers of 8.8±1.4 during AVNRT and 5.3±1.3 during SR. The number of ablation points was 3.6±1.5 for the FP-guided cryoablation (n=32) (Bonferroni corrected P<0.05 vs. anatomical RF; and P<0.05 vs. FP-guided RF), 5.4±2.1 for the FP-guided RF ablation (n=11) (P=0.0825 vs. anatomical RF), and 8.2±3.2 for the conventional RF ablation (n=10). Transient AV block occurred in 11 patients (21%). All AV block sites overlapped with the TDP area in the phase just before the His potential during AVNRT and SR, with a confidence setting of ≥24% (35[24-60]%). Conversely, in 42 patients without AV block, no ablation was performed in this area. Conclusion: The FP-guided cryoablation strategy targeting AVNRT termination required fewer cryoapplications than RF ablation. The RF/cryo application in the TDP area during SR and AVNRT posed a risk of AV block.
Open AccessFractionated Potential-Guided Cryoablation Targeting Termination of Atrioventricular Nodal Reentrant Tachycardia While Avoiding the Compact Node Electrogram
Background: Fractionated potential (FP) ablation during atrioventricular nodal reentrant tachycardia (AVNRT), is an effective strategy that minimizes redundant radiofrequency (RF) applications. This study aimed to evaluate the utility of cryoablation targeting FPs to effectively terminate AVNRT while further minimizing redundant cryoapplications. Moreover, we observed what appeared to be compact AVN (cAVN) or proximal His potentials—tiny, dull potentials (TDPs) with continuity to the His potential during sinus rhythm (SR) and AVNRT—in the anteroseptal area. The second aim of this study was to explore the significance of those potentials. Methods: Analyzed were 53 slow-fast AVNRT patients who underwent ablation procedures. Ultra-high resolution activation maps in the triangle of Koch were obtained during SR (n=34) and AVNRT (n=46). TDPs during SR and AVNRT in the anteroseptal area were identified and annotated using the LUMIPOINT Activation Search tool. Results: FP areas were observed in 19 patients (56%) during SR and in 46 (100%) during AVNRT. This area corresponded to the AVNRT termination and/or successful ablation site in all, with peak numbers of 8.8±1.4 during AVNRT and 5.3±1.3 during SR. The number of ablation points was 3.6±1.5 for the FP-guided cryoablation (n=32) (Bonferroni corrected P<0.05 vs. anatomical RF; and P<0.05 vs. FP-guided RF), 5.4±2.1 for the FP-guided RF ablation (n=11) (P=0.0825 vs. anatomical RF), and 8.2±3.2 for the conventional RF ablation (n=10). Transient AV block occurred in 11 patients (21%). All AV block sites overlapped with the TDP area in the phase just before the His potential during AVNRT and SR, with a confidence setting of ≥24% (35[24-60]%). Conversely, in 42 patients without AV block, no ablation was performed in this area. Conclusion: The FP-guided cryoablation strategy targeting AVNRT termination required fewer cryoapplications than RF ablation. The RF/cryo application in the TDP area during SR and AVNRT posed a risk of AV block.